AngioDynamics Announces Plan to Launch NeverTouch(TM) VenaCure(R) Product Line.Improved System Will Continue to Serve Varicose Vein varicose vein, superficial vessel that is abnormally lengthened, twisted, or dilated, seen most often on the legs and thighs. Varicose veins develop spontaneously, and are usually attributed to a hereditary weakness of the vein; the valves in the vein that keep the Market QUEENSBURY, N.Y. -- AngioDynamics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ANGO ANGO Algemene Nederlandse Gehandicapten Organisatie (Dutch: Equal Opportunities for Persons with Disabilities) ) announced today plans to launch the NeverTouch VenaCure procedure kit for laser treatment of severe varicose veins Varicose Veins Definition Varicose veins are dilated, tortuous, elongated superficial veins that are usually seen in the legs. Description . The improved VenaCure design will employ a proprietary laser fiber technology designed to provide an enhanced level of perforation per·fo·ra·tion n. 1. The act of perforating or the state of being perforated. 2. An abnormal opening in a hollow organ or viscus, as one made by rupture or injury. Perforation A hole. protection by further preventing contact between the fiber tip and the vessel wall during treatment. The Company currently plans to implement its NeverTouch technology within the current fiscal quarter to ensure continuation of its leadership position in the marketplace. "Our goal is to rapidly transition to a new fiber design ensuring that our customers do not experience any interruption of service," said Eamonn P. Hobbs, AngioDynamics' president and chief executive officer. "The new product line possesses a number of improvements, which is very much in line with AngioDynamics' goal of providing patients and the physicians who treat them with the best devices for endovenous therapy treatment." The upcoming product introduction follows a jury verdict returned Wednesday, March 28, in the Federal District Court in Boston, Massachusetts, ruling that AngioDynamics had unwillfully infringed on U.S. patent No. 6,398,777 with its VenaCure product line. In parallel with the new product introduction, AngioDynamics is filing a motion to overturn the verdict About AngioDynamics AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. products, embolization embolization /em·bo·li·za·tion/ (em?bo-li-za´shun) 1. the process or condition of becoming an embolus. 2. therapeutic introduction of a substance into a vessel in order to occlude it. products and venous products. More information is available at www.angiodynamics.com. Safe Harbor The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion